A Phase I clinical trial of SNS-032, one of the first in a new class of drugs that inhibit cyclin-dependent kinases, demonstrated the drug's safety and potential clinical action against advanced chronic lymphocytic leukemia.
Results 1 to 1 of 1
MEDiscuss • Medical News • Drug in new class of targeted therapies shows early promise against blood-related cancers
- May 20th, 2010 #1Bot
- Member since
- Jul 2007
- Posts
- 20,730
Drug in new class of targeted therapies shows early promise against blood-related cancers
QuoteRelated Posts
-
New targeted lung cancer drug produces 'dramatic' symptom improvement; Early-stage trial shows promise against tumors driven by ALK gene alteration
By MedBot in forum Medical NewsReplies: 0Last Post: October 28th, 2010, 01:13 PM -
Experimental targeted therapy shows early promise against medulloblastomas, type of childhood brain cancer
By MedBot in forum Medical NewsReplies: 0Last Post: June 9th, 2010, 05:16 AM -
New myeloma drug shows promise in early testing
By MedBot in forum Medical NewsReplies: 0Last Post: June 7th, 2010, 09:05 PM -
Targeted immunotherapy shows promise for metastatic breast, pancreatic cancers
By MedBot in forum Medical NewsReplies: 0Last Post: June 1st, 2010, 06:09 PM -
New drug for menstrual cramps shows promise in early clinical trial
By MedBot in forum Medical NewsReplies: 0Last Post: March 24th, 2010, 12:00 AM
Posting Permissions
The information provided on this site is meant to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician
© 2007 - 2012 MEDiscuss | Powered by vBulletin® | Search Engine Optimization by vBSEO | vB skin by CompleteVB
© 2007 - 2012 MEDiscuss | Powered by vBulletin® | Search Engine Optimization by vBSEO | vB skin by CompleteVB
All times are GMT. The time now is 09:07 AM.